LIBERTY-CUPID Study C Confirms Benefit of Dupilumab in Biologic-Naive CSU - HCPLive
LIBERTY-CUPID Study C confirms dupilumab's efficacy in reducing itch and disease activity in uncontrolled chronic spontaneous urticaria (CSU) patients. Dupilumab met primary and key secondary endpoints, with a 30% complete response rate in dupilumab-treated patients compared to 18% in the placebo group. Safety results were consistent with dupilumab's known profile, and Sanofi plans to share these data with the FDA to support an sBLA for CSU treatment.
Reference News
LIBERTY-CUPID Study C confirms dupilumab's efficacy in reducing itch and disease activity in uncontrolled chronic spontaneous urticaria (CSU) patients. Dupilumab met primary and key secondary endpoints, with a 30% complete response rate in dupilumab-treated patients compared to 18% in the placebo group. Safety results were consistent with dupilumab's known profile, and Sanofi plans to share these data with the FDA to support an sBLA for CSU treatment.